Your session is about to expire
← Back to Search
Cediranib + Olaparib for Cancer
Study Summary
This trial is testing a combination of two drugs to treat patients with solid tumors. Cediranib maleate blocks enzymes needed for cell growth, and olaparib may make the tumor more sensitive to Cediranib maleate.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 53 Patients • NCT01132820Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You need to have certain levels of blood cells and chemicals in your blood for this study.You have been diagnosed with certain types of cancer that has spread or cannot be removed with surgery.You are using natural herbal products, alternative medications, or folk remedies.You have had a significant amount of coughing up blood or bleeding in the past month.You have been classified as having severe heart failure by your doctor.You are able to perform daily activities without help or with some help.You have had another type of cancer in the past 3 years.You should not have any blood clotting or bleeding problems.You have a hole in the middle of a lung lesion.You currently have a heart rhythm problem that needs to be treated with medication.You do not have signs of myelodysplastic syndrome or acute myelogenous leukemia in your blood or bone marrow samples.Any side effects from previous treatment should be minor according to the National Cancer Institute's grading system.You are expected to live for at least 4 more months.You have had a stroke or mini-stroke in the last 6 months before joining the study.You have already tried at least one standard treatment for your advanced or spreading cancer.You have had allergic reactions to drugs similar to cediranib or olaparib.You have untreated cancer that has spread to your brain or spinal cord, or you have symptoms from cancer that has spread to your brain covering.You had a heart attack within the 6 months before signing up for the study.You must have a way for the doctors to measure your disease according to specific guidelines.You are taking medications or substances that strongly affect how your body processes certain drugs.You have a severe illness, ongoing infection, or mental health issues that could make it hard for you to follow the study rules.You have already taken a medication that blocks VEGF signaling and a PARP inhibitor together.You have certain factors that make you more likely to have heart problems, and you need to have a heart scan showing normal function within the last 3 months.You had a major surgery or significant injury within the last 28 days before starting cediranib.You have HIV and are taking a combination of drugs to manage it.You have a serious condition affecting your blood vessels in your arms or legs, or a bulge in the main blood vessel in your abdomen.Your thyroid function and blood pressure are well-managed.
- Group 1: Treatment (cediranib maleate, olaparib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities for participants to join this research program?
"This research trial is currently not recruiting new participants. It was first publicized on April 26th 2016 and was last edited November 8th 2022. Although this study has closed, there are 7184 other studies available at present that would welcome enrolment."
Is this an innovative research project?
"Since the original trial sponsored by AstraZeneca in 2005, cediranib maleate has gone on to receive Phase 1 drug approval and is currently being studied at 193 sites across 59 nations."
What afflictions is Cediranib Maleate employed to treat?
"Cediranib Maleate is frequently prescribed to help manage advance directives. It can also be beneficial for patients suffering from malignant neoplasm of ovary, primary peritoneal cancer, or sensory disturbances."
How many sites are overseeing this clinical investigation?
"Presently, 12 different sites are hosting this clinical trial. Toronto, Tampa and New Haven are three of the locations, but there are 9 other places around North America that have been selected as well. If you choose to join this research effort, it is helpful to select a clinic which is nearby in order to reduce time spent travelling."
Could you provide some examples of Cediranib Maleate research that has been conducted in the past?
"Currently, 193 medical trials involving cediranib maleate are underway, with 27 of those at the Phase 3 level. Although Houston, Texas is where a majority of these research initiatives take place, there are in fact 9498 sites running this medication trial."
Has the Food and Drug Administration accepted Cediranib Maleate for public use?
"Our team at Power assessed the safety of Cediranib Maleate as a 2. This is because there has been some evidence collected to support its security, yet no clinical data demonstrating its efficacy."
How many individuals are participating in this research project?
"Unfortunately, enrollment for this trial is currently closed. It was first posted in April of 2016 and last updated on November 8th 2022. However, 6991 studies are actively seeking participants to examine triple negative breast carcinoma while 193 trials demand involvement from those taking Cediranib Maleate medication."
Share this study with friends
Copy Link
Messenger